Predicting response to epigenetic therapy

摘要

Drugs targeting the epigenome are new promising cancer treatment modalities; however,not all patients receive the same benefit from these drugs. In contrast toconventional chemotherapy, responses may take several months after the initiation oftreatment to occur. Accordingly, identification of good pretreatment predictors ofresponse is of great value. Many clinical parameters and molecular targets have beentested in preclinical and clinical studies with varying results, leaving room foroptimization. Here we provide an overview of markers that may predict the efficacy ofFDA- and EMA-approved epigenetic drugs.